Supported By: Dexcom

Program Description

Real-time continuous glucose monitoring (rtCGM) facilitates the recognition of patient-specific trends of hyper- and hypoglycemia, allowing for individualized management and behavior modification. Data continue to emerge to support the use of rtCGM in a variety of settings and conditions, including primary care, outpatient, and in-hospital (intensive care unit [ICU] and non-ICU) settings, and in conditions such as type 2 diabetes and pregnancy. Mark your calendars and join us for a live 90-minute symposium led by 3 preeminent faculty who have successfully implemented rtCGM in various patient types. Bring your questions! Our faculty will answer as many as they can at the end of the presentations and an expert diabetes faculty dedicated for online learners will answer questions throughout.

For more information and to register, please visit: www.medscape.org/symposium/updates-rtcgm-2024

Target Audience

This activity is intended for diabetologists and endocrinologists, primary care physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians who treat patients with type 2 diabetes and other metabolic abnormalities.

Goal Statement

The goal of this activity is for learners to be better able to understand the role of real-time continuous glucose monitoring in various patient types.

Learning Objectives

Upon completion of this activity, participants will:

• Have increased knowledge regarding the data supporting rtCGM use for various patient types
• Have greater competence related to use of rtCGM in various patient types
• Demonstrate greater confidence in their ability to use data from rtCGM to improve the management of patients with metabolic conditions

Accreditation Statement

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses

​Awarded ​1.50​ contact hour(s) of nursing continuing professional development for RNs and APNs.

For Pharmacists

Medscape designates this continuing education activity for ​1.50​ contact hour(s) (​0.150​ CEUs) (Universal Activity Number: ​JA0007105-0000-24-068-L01-P​).

This activity was planned by and for the healthcare team, and learners will receive ​1.50​ Interprofessional Continuing Education (IPCE) credit for learning and change.

For more information and to register, please visit: www.medscape.org/symposium/updates-rtcgm-2024

This information is being distributed by the American Diabetes Association as a sponsor benefit. Reference to commercial products, processes, or services by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the American Diabetes Association. The views and opinions of sponsors expressed herein do not necessarily state or reflect those of the American Diabetes Association, and shall not be used for advertising or product endorsement purposes.

Speakers

Chairperson
Richard M Bergenstal, MD
International Diabetes Center – HealthPartners Institute
Executive Director
Minneapolis, MN

Virtual Chairperson
Davida F. Kruger, MSN, APN-BC, BC-ADM
Henry Ford Health System
Division of Endocrinology, Diabetes and Bone Disorders
Detroit, MI

Faculty
Kathleen M. Dungan, MD, MPH
The Ohio State University
Division of Endocrinology, ​Diabetes and Metabolism
Professor of Medicine
Columbus, OH

Faculty
Joseph Reed, MD
Case Western/University Hospitals
Harrington Heart & Vascular Institute
PGY-3 Internal Medicine
Cleveland, OH

---

Resources

Learn more and register